A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
about
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureusEfficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysisCurrent and Future Considerations for the Treatment of Hospital-Acquired PneumoniaSystematic Review and Meta-Analysis of the Efficacy and Safety of Telavancin for Treatment of Infectious Disease: Are We Clearer?Update on the emerging role of telavancin in hospital-acquired infectionsTelavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogensVancomycin revisited - 60 years laterClinical management of Staphylococcus aureus bacteremia: a review.Oritavancin for acute bacterial skin and skin structure infections.Case-Control Study of Telavancin as an Alternative Treatment for Gram-Positive Bloodstream Infections in Patients with Cancer.Telavancin (VIBATIV) for the treatment of complicated skin and skin structure infections.Telavancin: the long and winding road from discovery to food and drug administration approvals and future directions.Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.Treatment of Staphylococcus aureus Infections.Pharmacokinetics of Telavancin at Fixed Doses in Normal Body Weight and Obese (Classes I, II, and III) Adult Subjects.Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia.Pharmacokinetic/pharmacodynamic parameters for treatment optimization of infection due to antibiotic resistant bacteria: a summary for practical purposes in children and adults.Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.
P2860
Q27027412-F30DB11A-B16B-4CCB-BF25-F127DD4C5182Q28070326-28F688C8-F366-4915-99CF-F77902DE3FFEQ28071882-043B4280-58E8-4B15-B87D-B0FAE81BBD5FQ28078557-6B552AAF-E0C9-46D7-AFF0-4A399445DDE7Q28083522-8EB11A78-CFF8-403C-8B70-4F86BA4DC340Q33788308-AE266374-BE33-437C-8F64-18267B0B7B8CQ34433066-3472FDE7-753E-405C-A330-B9FFAB43EAB0Q34441035-A3936921-7285-4AEC-9924-7DFA8592C775Q36086423-AA165ACF-128B-4D8E-868A-B494B4492896Q36439168-BDA6ADBF-F6B7-433D-9685-17CD4B4FBA29Q38522574-AEA609AB-59F2-4781-8596-15A2B057D057Q38575714-CB7563B0-C554-49DD-8687-A8C2930F74D5Q38646905-2366C5EF-9E71-4DB7-88CD-13710669A04FQ39061989-2AE80118-10DE-4A52-ADB8-B7F929E541D7Q40049973-46644B52-31C5-4DA5-9662-96C780C16D89Q47172132-58337251-D0C8-478A-A9A7-8666F3807935Q47634145-D33BAC31-E7FB-4DA5-9862-74E08E5A0262Q48197188-17BB63C3-C243-4D46-9574-3AE81859C823Q50065370-7585ED7B-D7DE-4526-83B8-01DA86B8826D
P2860
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A randomized Phase 2 trial of ...... bacteremia: the ASSURE study.
@ast
A randomized Phase 2 trial of ...... bacteremia: the ASSURE study.
@en
type
label
A randomized Phase 2 trial of ...... bacteremia: the ASSURE study.
@ast
A randomized Phase 2 trial of ...... bacteremia: the ASSURE study.
@en
prefLabel
A randomized Phase 2 trial of ...... bacteremia: the ASSURE study.
@ast
A randomized Phase 2 trial of ...... bacteremia: the ASSURE study.
@en
P2093
P2860
P356
P1476
A randomized Phase 2 trial of ...... bacteremia: the ASSURE study.
@en
P2093
Arnold Lentnek
G Ralph Corey
John Pullman
Jose M Miró
Martin E Stryjewski
Michael M Kitt
Steven L Barriere
William O'Riordan
P2860
P2888
P356
10.1186/1471-2334-14-289
P577
2014-05-23T00:00:00Z
P5875
P6179
1022285422